MicroCarb Inc. on Tuesday said it has developed a prototypediagnostic receptor-based assay for verocytotoxin-producingbacteria.

The Gaithersburg, Md., company said its assay is the first rapiddiagnostic for E. coli 0157:H7, as well as for other toxigenicserotypes in humans, animals or foodstuffs.

MicroCarb's technology is based on carbohydrates that occurnaturally in humans and animals and that are receptors for theattachment of disease-producing bacteria and their toxins.

The test could be on the market by June, according toMicroCarb, and could yield gross revenues of $2 million withinthe first 18 months and $15 million to $20 million annuallyover the next three to five years, the company said.

The company is negotiating manufacturing and distributionagreements with potential partners for designated markets.

(c) 1997 American Health Consultants. All rights reserved.